The therapeutic effect of probiotic bacteria on gastrointestinal diseases

Advances in Clinical and Experimental Medicine

Volumn 22, Issue 5, 2013, Pages 759-766

  Sarowska, Jolanta ^a   Choroszy Król, Irena ^a   Regulska Ilow, Bozena ^a   Frej Ma̧drzak, Magdalena ^a   Jama Kmiecik, Agnieszka ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Gastrointestinal diseases; Probiotics

Indexed keywords

AMOXICILLIN; AMPICILLIN; BACTERIAL TOXIN; CEPHALOSPORIN; CLINDAMYCIN; LACTOSE; MESALAZINE; PLACEBO; PROBIOTIC AGENT; VSL3;

ACUTE DIARRHEA; ANTIBIOTIC ASSOCIATED DIARRHEA; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BIFIDOBACTERIUM; CANCER PREVENTION; CARDIOVASCULAR DISEASE; CELLULAR IMMUNITY; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED CLINICAL TRIAL (TOPIC); CROHN DISEASE; DRUG FORMULATION; DRUG MECHANISM; ENTERITIS; GASTROINTESTINAL DISEASE; GRAM POSITIVE BACTERIUM; HOST PATHOGEN INTERACTION; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; INFECTION PREVENTION; INFECTIOUS DIARRHEA; INTESTINE FLORA; INTESTINE INFECTION; IRRITABLE COLON; LACTOBACILLUS; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS BULGARICUS; LACTOBACILLUS CASEI; LACTOBACILLUS RHAMNOSUS; META ANALYSIS (TOPIC); NECROTIZING ENTEROCOLITIS; NONHUMAN; NUTRITIONAL TOLERANCE; OPTIMAL DRUG DOSE; OUTCOME ASSESSMENT; REVIEW; SACCHAROMYCES BOULARDII; STREPTOCOCCUS THERMOPHILUS; TRAVELLER DIARRHEA; ULCERATIVE COLITIS;

BACTERIA (MICROORGANISMS); BIFIDOBACTERIUM; LACTOBACILLUS;

ANIMALS; DIARRHEA; ENTEROCOLITIS, NECROTIZING; GASTROINTESTINAL DISEASES; HUMANS; INFLAMMATORY BOWEL DISEASES; IRRITABLE BOWEL SYNDROME; PROBIOTICS;

EID: 84891414790     PISSN: 18995276     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Neish AS: Microbes in gastrointestinal health and disease. Rev Bas Clin Gastroenterol 2009, 136, 65-80.
2. Metchnikoff E: The prolongation of life. New York: G.P. Putnom & Sons 1907.
3. Nissle A: Die antagonistische Behandlung chronischer Darmstorungen mit Colibakterien. Med Klin 1918, 2, 29-33.
4. Vasiljevic T, Shah NP: Probiotics - from Metchnikoff to bioactives. Int Dairy J 2008, 18, 714-728.
5. Vergin F: Anti- und Probiotika. Hippokrates 1954, 25, 16-119.
6. Joint FAO/WHO Working Group Report on Drafting Guidelines for the Evaluation of Probiotics in Food. London, Ontario, Canada, April 30 and May 1, 2002.
7. Madsen K, Jijon H, Yeung H: DNA from probiotic bacteria exerts anti-inflammatory actions on epithelial cells by inhibition of NFκB. Gastroenterol 2002, 122, Abstract 546.
8. Rachmilewitz D, Karmeli F, Takabayashi K: Amelioration of experimental colitis by probiotics is due to the immunostimulatory effect of its DNA. Gastroenterol 2002, 122, Abstract T1004.
9. Naidu AS, Bidlack WR, Clemens RA: Probiotic spectra of lactic acid bacteria (LAB). Crit Rev Food Sci Nutr 1999, 39, 13-126. (Pubitemid 129507861)
10. Moneta J, Libudzisz Z: Suitability of Lactobacillus strains as components of probiotics. [In:] Food Biotechnology. Vol. 17 Progress in Biotechnology, Elsevier Science B.V., Amsterdam, The Netherlandes 2000, 257-264.
11. Schrezenmeir J, de Vrese M: Probiotics, prebiotics, and synbiotics - approaching a definition. Am J Clin Nutr 2001, 73, 361-364.
12. Madaliński K, Szajewska H: Probiotics: mechanism of action, immunomodulation and potential use in gastrointestinal diseases. Zakazenia 2004, 5, 42-48.
13. Czerwionka-Szaflarska M, Romańczuk B: Probiotics - which, whom, when? Przew Lek 2008, 1, 214-221.
14. Servin AL: Antagonistic activities of lactobacilli and bifidobacteria against microbial pathogens. FEMS Microbiol Rev 2004, 28, 405-40.
15. Elmer GW: Probiotics: "living drugs". Am J Health Syst Pharm 2001, 58, 1101-1109.
16. Ruszczyński M, Radzikowski A, Szajewska H: Clinical trial: effectiveness of Lactobacillus rhamnosus (strains E/N, Oxy and Pen) in the prevention of antibiotic-associated diarrhoea in children. Alimentary Pharmacol Therap 2008, 28, 154-161. (Pubitemid 351782820)
17. Alakomi HL, Skytta E, Saarela M, Mattila-Sandholm T, Latva-Kala K, Helander IM: Lactic acid permeabilizes gram-negative bacteria by disrupting the outer membrane. Appl Environ Microbiol 2000, 66, 2001-2005. (Pubitemid 30253724)
18. Chen X, Kokkotou EG, Mustafa N, Bhaskar KR, Sougioultzis S: Saccharomyces boulardii inhibits ERK1/2 mitogen-activated protein kinase activation both in vitro and in vivo and protects against Clostridium difficile toxin A-induced enteritis. J Biol Chem 2006, 281, 24449-24454. (Pubitemid 44274218)
19. Wold AE: Immune effects of probiotics. Scand J Nutr 2001, 45, 76-85.
20. PharmacoEconomics & Outcomes News: Recommendations for the use of probiotics have been released following the Advances in Clinical Use of Probiotics Workshop. 9 August 2008, Volume, Issue 559, 5, Guideline.
21. Vandenplas Y, De Hert SG: Randomised clinical trial: the synbiotic food supplement probiotical vs. placebo for acute gastroenteritis in children. Aliment Pharmacol Ther 2011, 34, 862-867.
22. Boyle RJ, Robins-Browne RM, Tang ML: Probiotic use in clinical practice: what are the risks? Am J Clin Nutr 2006, 83, 1256-1264. (Pubitemid 44713053)
23. Casburn-Jones AC, Farthing MJ: Management of infectious diarrhoea. Gut 2004, 53, 296-305. (Pubitemid 38125522)
24. Guarino A, Albano F, Ashkenazi S, Gendrel D, Hoekstra JH, Shamir R, Szajewska H: European Society for Paediatric Gastroenterology, Hepatology, and Nutrition/European Society for Paediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe: executive summary. J Pediatr Gastroenterol Nutr 2008, 46, 619-621.
25. Guandalini S: Probiotics for prevention and treatment of diarrhea. J Clin Gastroenterol 2011, 149-153.
26. Le Luyer B, Makhoul G, Duhamel JF: Étude multicentrique, contrôlée en double insu d'une formule adaptée enrichie en Saccharomyces boulardii dans le traitement des diarhées aiguës du nourisson. Archiv Pediatrie 2010, 17, 459-465.
27. Allen SJ, Okoko B, Martinez E, Gregorio G, Dans LF: Probiotics for treating infectious diarrhoea. Cochrane Database Syst Rev 2004, CD003048.
28. Corrêa N, Penna F, Lima F, Nicoli J, Péret Filho L: Treatment of acute diarrhea with Saccharomyces boulardii in infants: a double-blind, randomized, placebo controlled trial. J Clin Gastroenterol 2011, 149-153.
29. Canani RB, Cirillo P, Terrin G, Cesarano L, Spagnuolo MI, De VA, Albano F, Passariello A, De MG, et al.: Probiotics for treatment of acute diarrhoea in children: randomised clinical trial of five different preparations. BMJ 2007, 335, 340-345.
30. Sazawal S, Hiremath G, Dhingra U, Malik P, Deb S, Black RE: Efficacy of probiotics in prevention of acute diarrhoea: a meta-analysis of masked, randomised, placebo-controlled trials. Lancet Infect Dis 2006, 6, 374-382. (Pubitemid 43737276)
31. Szajewska H, Hoekstra JH, Sandhu B: Management of acute gastroenteritis in Europe and the impact of the new recommendations: a multicenter study. The Working Group on acute Diarrhoea of the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr 2000, 30, 522-527. (Pubitemid 27216867)
32. Szajewska H, Mrukowicz JZ: Probiotics in the treatment and prevention of acute infectious diarrhea in infants and children: a systematic review of published randomized, double-blind, placebo-controlled trials. J Pediatr Gastroenterol Nutr 2001, 33, 17-25.
33. Szajewska H, Skorka A, Dylag M: Meta-analysis: Saccharomyces boulardii for treating acute diarrhoea in children. Aliment Pharmacol Ther 2007, 25, 257-264. (Pubitemid 46115395)
34. Szajewska H, Skorka A, Ruszczynski M, Gieruszczak-Bialek D: Meta-analysis: Lactobacillus GG for treating acute diarrhoea in children. Aliment Pharmacol Ther 2007, 25, 871-881. (Pubitemid 46525343)
35. Aggett PJ, Agostoni C, Axelsson I, Braegger C, Goulet O, Koletzko B, Michaelsen KF, Rigo J, Shamir R, Szajewska H, Turck D, Weaver LT: Probiotic bacteria in dietetic products for infants: A Commentary by the ESPGHAN Committee on Nutrition. J Pediatr Gastroenterol Nutr 2004, 38, 4, 365-374.
36. Maldonaldo J, Lara-Villoslada F, Sierra S, Sempere L, Gomez M, Rodriguez JM, Boza J, Xaus J, Olivares M: Safety and tolerance of the human milk probiotic strain Lactobacillus salivarius CECT5713 in 6-month-old children. Nutrition 2010, 26, 1082-1087.
37. Gascón J: Epidemiology, etiology and pathophysiology of traveler's diarrhea. Digestion 2006, 73, 1, 102-108.
38. Al-Abri SS, Beeching NJ, Nye FJ: Traveller's diarrhoea. Lancet Infect Dis 2005, 5, 349-360. (Pubitemid 40779256)
39. McFarland LV: Meta-analysis of probiotics for the prevention of traveler's diarrhea. Travel Med Infect Dis 2007, 5, 97-105.
40. Szajewska H, Ruszczynski M, Radzikowski A: Probiotics in the prevention of antibiotic-associated diarrhea in children: a meta-analysis of randomized controlled trials. J Pediatr 2006, 149, 367-372.
41. Ruszczynski M, Radzikowski A, Szajewska H: Clinical trial: effectiveness of Lactobacillus rhamnosus (strains E/N, Oxy and Pen) in the prevention of antibiotic-associated diarrhoea in children. Alimentary Pharmacol Therap 2008, 28, 154- 161.
42. Hickson M, D'Souza AL, Muthu N: Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. BMJ 2007, 335, 80.
43. McFarland LV: Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol 2006, 101, 812-822.
44. Hickson M, D'Souza AL, Muthu N, Rogers TR, Want S, Rajkumar C, Bulpitt CJ: Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomized double blind placebo controlled trial. BMJ 2007, 335, 80.
45. Rohde CL, Bartolini V, Jones N: The use of probiotics in the prevention and treatment of antibiotic-associated diarrhea with special interest in Clostridium difficile-associated diarrhea. Nutr Clin Pract 2009, 24, 33-40.
46. Lin HC, Su BH, Chen AC: Probiotics may reduce risk of necrotizing enterocolitis in very low birth weight infants. Pediatrics 2005, 115, 1-4.
47. Deshpande G, Rao S, Patole S, Bulsara M: Updated meta-analysis of probiotics for preventing necrotizing enterocolitis in preterm neonates. Pediatrics 2010, 125, 5, 921-930.
48. Deshpande G, Rao S, Patole S: Probiotics for prevention of necrotising enterocolitis in preterm neonates with very low birth weight: a systemic review of randomized controlled trials. Lancet 2007, 369, 1614-1620. (Pubitemid 46710124)
49. Mihatsch WA, Braegger CP, Decsi T: Critical systematic review of the level of evidence for routine use of probiotics for reduction of mortality and prevention of necrotizing enterocolitis and sepsis in preterm infants. Clinical Nutri 2012, 31, 1, 6-15.
50. Fedorak RN: Probiotics in the management of ulcerative colitis. Gastroenterol Hepatol (NY) 2010, Nov, 6, 11, 688-690.
51. Floch MH: Probiotic therapy for ulcerative colitis. J Clin Gastroenterol 2010, Apr, 44, 4, 237-238.
52. Miele E, Pascarella F, Giannetti E, Quaglietta L, Baldassano RN, Staiano A: Effect of aprobiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol 2009, 104, 437-443.
53. Kruis W, Fric P, Pokrotnieks J: Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004, 53, 1617-1623. (Pubitemid 39434105)
54. Shanahan F: Crohn's disease. Lancet 2002, 359, 62-69.
55. Prantera C: Probiotics for Crohn's disease: what have we learned? Gut 2006, 55, 6, 757-759.
56. Hedin C, Whelan K, Lindsay JO: Evidence for the use of probiotics and prebiotics in inflammatory bowel disease: a review of clinical trials. Proc Nutr Soc 2007, 66, 307-315. (Pubitemid 47076227)
57. McFarland LV, Dublin S: Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J Gastroenterol 2008, May, 7, 14, 17, 2650-2661.
58. Sawant PD, Venkatramant J, Ducrotte P: Evaluation of Lactobacillus plantarum 299v Efficacy in IBS: Results of a Randomized Placebo-Controlled Trial in 200 Patients. Gastroenterol 2010, DDW.
59. Kruis W, Chrubasik S, Boehm S: A double-blind placebocontrolled trial to study therapeutic effects of probiotic Escherichia coli Nissle 1917 in subgroups of patients with irritable bowel syndrome. Int J Colorectal Dis 2012, 27, 467-474.
60. Rogers NJ, Mousa SA: The shortcomings of clinical trials assessing the efficacy of probiotics in irritable bowel syndrome. J Altern Complement Med 2012, Feb, 18, 2, 112-119.